Tricida, Inc. focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
- Sector(s): Healthcare
- Industry: Biotechnology
- Full Time Employees: 57
- Incorporated in 2013
- Headquartered in South San Francisco, California
- https://www.tricida.com
No comments:
Post a Comment